The article points to the growing scale of challenges related to drug availability, from disruptions in supply chains to decisions by global corporations to withdraw from the human insulin market in Europe. In this context, BIOTON is presented as the only domestic manufacturer that has been conducting integrated insulin production for over 25 years – from the biosynthesis of the active substance to the finished product – and has the potential to secure demand not only in Poland but also throughout the EU.
The article also highlights the company’s investments in infrastructure development and the implementation of environmentally friendly solutions in line with ESG principles, as well as intensive work on a new generation of biotechnological drugs, including insulin analogues.
Being featured in Forbes is an important moment for BIOTON – it shows that our activities and expertise are recognized among experts, industry media, and opinion leaders. It also confirms that Polish biotechnology has a real impact on shaping the future of pharmacy in Europe.
We encourage you to read the full article:
https://www.forbes.pl/gospodarka/bioton-kontra-kryzys-lekow/zjhnhnz